ATH434 protects brain cells and improves motor function in Parkinsonian disorder
- Written by PR Newswire
Oral presentation at the American Academy of Neurology
 |
MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the...
